Literature DB >> 27780399

Management of Transient Monocular Vision Loss and Retinal Artery Occlusions.

Ivana Vodopivec1, Dean M Cestari1, Joseph F Rizzo1.   

Abstract

Acute transient or permanent retinal occlusive disease requires prompt medical attention and can be an ophthalmological emergency. Central retinal artery occlusion leads to permanent and severe monocular visual loss in the majority of patients. Transient monocular vision loss leaves no permanent deficits, but requires the same level of clinical vigilance, as it portends possible future adverse events, including loss of vision and stroke. Acute treatment options remain limited, and secondary prevention of cerebral ischemic events is the mainstay of management. This article reviews the current evidence for managing patients with retinal ischemia.

Entities:  

Keywords:  Branch retinal artery occlusion; central retinal artery occlusion; embolism; giant cell arteritis; retinal vasospasm; transient monocular vision loss

Mesh:

Year:  2016        PMID: 27780399     DOI: 10.1080/08820538.2016.1228417

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  4 in total

1.  Acute retinal arterial ischemia.

Authors:  Michael Dattilo; Nancy J Newman; Valérie Biousse
Journal:  Ann Eye Sci       Date:  2018-06-06

2.  The Retrobulbar Spot Sign and Prominent Middle Limiting Membrane as Prognostic Markers in Non-Arteritic Retinal Artery Occlusion.

Authors:  Marlena Schnieder; Charlotte V Fischer-Wedi; Sebastian Bemme; Mai-Linh Kortleben; Nicolas Feltgen; Jan Liman
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

3.  Recurrent migraine with binocular transient vision loss associated with acute stroke: A case report.

Authors:  Nabita Aulia; Yunita Mansyur; Batari Todja Umar; Anastasia Vanny Launardo
Journal:  Ann Med Surg (Lond)       Date:  2021-11-11

4.  Clinical Analysis of 42 Cases of Ocular Ischemic Syndrome.

Authors:  Jingyi Luo; Zhichao Yan; Yu Jia; Rongjiang Luo
Journal:  J Ophthalmol       Date:  2018-03-11       Impact factor: 1.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.